Latest Nikolaus Friedreich Stories
WALTHAM, Mass., Dec. 15 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today announced that the Company has received $731,000 in research funding to support the ongoing development of new treatments for Friedreich's ataxia from the Muscular Dystrophy Association (MDA).
Discovery takes researchers 1 step closer to human clinical trials and could improve understanding of other diseases.
WALTHAM, Mass., Sept. 25 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) reported today publication of research that identifies histone deacetylase 3 (HDAC 3) as an important enzyme target for therapeutic intervention in Friedreich's ataxia.
ST. PETERSBURG, Fla., Dec. 22 /PRNewswire/ -- On December 17th, the new Bonefish Grill restaurant located at 5062 4th Street North in St.
LIESTAL, SWITZERLAND--(Marketwire - Oct. 10, 2008) - Santhera Pharmaceuticals (SWX:SANN), a Swiss specialty pharmaceutical company with a focus on neuromuscular diseases, announced today the launch of CATENA(R) (idebenone) in Canada.
Santhera Pharmaceuticals has announced that Health Canada has approved SNT-MC17/idebenone, subject to certain conditions, for the treatment of Friedreich's Ataxia. Health Canada's decision is said to be the first marketing authorization worldwide for any Friedreich's Ataxia therapy.
- A transitional zone between two communities containing the characteristic species of each.